StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the stock. Mizuho lowered their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. Barclays reduced their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday, November 8th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Revance Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Trading Down 1.7 %

Shares of NASDAQ RVNC opened at $3.41 on Friday. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.59. The stock has a 50 day moving average of $3.86 and a 200-day moving average of $4.51. The company has a market capitalization of $355.97 million, a P/E ratio of -1.77 and a beta of 0.86.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. Analysts predict that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Revance Therapeutics

A number of large investors have recently modified their holdings of RVNC. Certuity LLC bought a new position in Revance Therapeutics in the second quarter valued at about $26,000. FORA Capital LLC bought a new stake in shares of Revance Therapeutics in the 3rd quarter valued at $54,000. Creative Planning acquired a new position in shares of Revance Therapeutics during the third quarter valued at about $56,000. Vanguard Personalized Indexing Management LLC acquired a new position in Revance Therapeutics during the 2nd quarter worth approximately $33,000. Finally, Accredited Investors Inc. bought a new position in shares of Revance Therapeutics in the 3rd quarter worth $67,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.